A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction

The incidence of breast reconstruction failure after conventional photon radiotherapy for breast cancer is about 18.7%. At present, there is limited data on proton radiotherapy for post operative breast cancer with implantation reconstruction. Proton radiotherapy for breast cancer can significantly reduce the radiation dose of the ipsilateral heart and lung, thereby reducing the incidence of cardiac events and radiation pneumonia. This study is aimed at the study of adjuvant hypofractionated intensity-modulated proton radiotherapy for post operative breast cancer with implantation reconstruction. It can provide an ideal treatment option for such patients to effectively protect the heart and lungs without increasing the failure rate of breast reconstruction after adjuvant radiotherapy.

Inclusion Criteria:1: Patients with pathologically confirmed breast cancer2: Indications: patients who need adjuvant radiotherapy after mastectomy and implant reconstruction3: No distant metastasis4: Had no chest and breast radiotherapy history5: Between the ages of 18 and 806: ECOG general status score is 0-2,There are no serious pulmonary hypertension, cardiovascular disease, peripheral vascular disease, serious chronic heart disease and other complications that may affect the radiotherapy7: Non pregnancy (confirmed by serum or urine β- HCG test) or lactating women8: The patient must sign the informed consent form for receiving radiotherapy.Exclusion Criteria:1: No pathological confirmation；2: Distant metastasis；3: Had chest and breast radiotherapy history4: Organs at risk could not achieve safe dose5: Pregnancy (confirmed by serum or urine β- HCG test) or lactating women6: Poor general health status, i.e. KPS<70, or ECOG>27: There are serious complications that may affect the radiotherapy, including: a) unstable angina, congestive heart failure and myocardial infarction requiring hospitalization in the past 6 months； b) Acute bacterial or systemic fungal infection；c) Chronic obstructive pulmonary disease exacerbation or other respiratory diseases need hospitalization； d) Patients with immunosuppression；e) With connective tissue disease, such as active scleroderma or lupus and other contraindications to radiotherapy；8: Unable to understand the purpose of treatment or unwilling/unable to sign informed consent.